Brett D. Dufour - Publications

Behavioral Neuroscience Oregon Health and Science University, Portland, OR 
Huntington's disease

8 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Liguore WA, Domire JS, Button D, Wang Y, Dufour BD, Srinivasan S, McBride JL. AAV-PHP.B Administration Results in a Differential Pattern of CNS Biodistribution in Non-human Primates Compared with Mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 31420242 DOI: 10.1016/j.ymthe.2019.07.017  1
2018 Dufour BD, McBride JL. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease. Neurobiology of Disease. PMID 30292559 DOI: 10.1016/j.nbd.2018.09.025  1
2016 Dufour BD, McBride JL. Corticosterone dysregulation exacerbates disease progression in the R6/2 transgenic mouse model of Huntington's disease. Experimental Neurology. PMID 27381424 DOI: 10.1016/j.expneurol.2016.06.028  0.96
2016 Dufour BD, McBride JL. Intravascular AAV9 Administration for Delivering RNA Silencing Constructs to the CNS and Periphery. Methods in Molecular Biology (Clifton, N.J.). 1364: 261-75. PMID 26472457 DOI: 10.1007/978-1-4939-3112-5_21  0.96
2014 Monteys AM, Spengler RM, Dufour BD, Wilson MS, Oakley CK, Sowada MJ, McBride JL, Davidson BL. Single nucleotide seed modification restores in vivo tolerability of a toxic artificial miRNA sequence in the mouse brain. Nucleic Acids Research. 42: 13315-27. PMID 25332397 DOI: 10.1093/nar/gku979  0.96
2014 Dufour BD, Smith CA, Clark RL, Walker TR, McBride JL. Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 797-810. PMID 24390280 DOI: 10.1038/mt.2013.289  0.96
2012 Shirendeb UP, Calkins MJ, Manczak M, Anekonda V, Dufour B, McBride JL, Mao P, Reddy PH. Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease. Human Molecular Genetics. 21: 406-20. PMID 21997870 DOI: 10.1093/hmg/ddr475  0.96
2011 McBride JL, Pitzer MR, Boudreau RL, Dufour B, Hobbs T, Ojeda SR, Davidson BL. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 2152-62. PMID 22031240 DOI: 10.1038/mt.2011.219  0.96
Show low-probability matches.